Neurochemical Studies of Early-Onset Alzheimer's Disease: Possible Influence on Treatment

New England Journal of Medicine

Volumn 313, Issue 1, 1985, Pages 7-11

  Francis, Paul T ^a   Palmer, Alan M ^a   Sims, Neil R ^a   Bowen, David M ^a   Davison, Alan N ^a   Esiri, Margaret M ^a   Neary, David ^a   Snowden, Julie S ^a   Wilcock, Gordon K ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; GLUCOSE;

ALZHEIMER DISEASE; AUTOPSY; CENTRAL NERVOUS SYSTEM; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CYTOLOGY; HUMAN; NERVOUS SYSTEM; PRIORITY JOURNAL;

EID: 0021797563     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198507043130102     Document Type: Article

References (38)

1. Herzog AG, Kemper TL. Amygdaloid changes in aging and dementia. Arch Neurol 1980; 37: 625–9.
2. Tomlinson BE, Irving D, Blessed G. Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J Neurol Sci 1981; 49: 419–28.
3. Price DL, Whitehouse PJ, Struble RG, et al. Basal forebrain cholinergic systems in Alzheimer's disease and related dementias. Neurosci Comment 1982; 1: 84–92.
4. Arendt T, Bigl V, Tennstedt A, Arendt A. Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer's disease. Neuroscience 1985; 14: 1–14.
5. Curcio CA, Kemper T. Nucleus raphe dorsalis in dementia of Alzheimer type: neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol 1984; 43: 359–68.
6. Pearce BR, Palmer AM, Bowen DM, Wilcock GK, Esiri MM, Davison AN. Neurotransmitter dysfunction and atrophy of the caudate nucleus in Alzheimer's disease. Neurochem Pathol 1984; 2: 221–32.
7. Rossor MN, Iversen LL, Reynolds GP, Mountjoy CQ, Roth M. Neurochemical characteristic of early and late onset types of Alzheimer's disease. Br Med J 1984; 288: 961–4.
8. Spillane JA, White P, Goodhardt MJ, Flack RHA, Bowen DM, Davison AN. Selective vulnerability of neurones in organic dementia. Nature 1977; 226: 558–9.
9. Smith CCT, Bowen DM, Sims NR, Neary D, Davison AN. Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer's disease. Brain Res 1983; 264: 138–41.
10. Francis PT, Bowen DM. Relevance of reduced concentrations of somatostatin in Alzheimer's disease. Biochem Soc Trans 1985; 13: 170–1.
11. Gottfries C.-G., Adolfsson R, Aquilonius SM, et al. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging 1983; 4: 261–71.
12. Palmer AM, Sims NR, Bowen DM, et al. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. J Neurol Neurosurg Psychiatry 1984; 47: 481–4.
13. Sims NR, Bowen DM, Smith CCT, et al. Glucose metabolism acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet 1980; 1: 333–6.
14. Sims NR, Bowen DM, Davison AN. 14C-Acetylcholine synthesis and 14C-carbon dioxide production from U-14C-glucose by tissue prisms from human neocortex. Biochem J 1981; 196: 867–76.
15. Sims NR, Bowen DM, Allen SJ, et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 1983; 40: 503–9.
16. Bowen DM, White P, Spillane JA, et al. Accelerated aging or selective neuronal loss as an important cause of dementia? Lancet 1979; 1: 11–14
17. Neary D, Snowden JS. Psychological correlates in presenile dementia. In: Rose FC, ed. Research progress in dementia. Basel: S Karger (in press).
18. Wilcock GK, Esiri MM. Plaques, tangles and dementia: a quantitative study. J Neurol Sci 1982; 56: 343–56.
19. Bowen DM, Allen SJ, Benton JS, et al. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem 1983; 41: 266–72.
20. Mefford IN, Gilberg M, Barchas JD. Simultaneous determination of catecholamines and unconjugated 3,4-dihydroxyphenylacetic acid in brain tissue by ion-pairing reverse-phase high-performance liquid chromatography with electrochemical detection. Anal Biochem 1980; 104: 469–72.
21. Arai H, Kosaka K, Iizuka R. Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem 1984; 43: 388–93.
22. Marek KL, Bowen DM, Sims NR, Davison AN. Stimulation of acetylcholine synthesis by blockade of presynaptic muscarinic inhibitory autoreceptors: observations in rat and human brain preparations and comparison with the effect of choline. Life Sci 1982; 30: 1517–24.
23. Palmer AM, Bowen DM. 5-Hydroxyindoleacetic acid and homovanillic acid in the CSF and caudate nucleus of histologically verified examples of Alzheimer's disease. Biochem Soc Trans 1985; 13: 167–8.
24. Cross AJ, Crow TJ, Johnson JA, et al. Monoamine metabolism in senile dementia of Alzheimer type. J Neurol Sci 1983; 60: 383–92.
25. Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981; 10: 184–92.
26. Ball MJ. Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with aging and dementia: a quantitative study. Acta Neuropathol (Berl) 1977; 37: 111–8.
27. Bowen DM. Biochemical assessment of neurotransmitter and metabolic dysfunction and cerebral atrophy in Alzheimer's disease. In: Katzman R, ed. Biological aspects of Alzheimer's disease. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory, 1983:219–31. (Banbury report 15).
28. Cross AJ, Crow TJ, Johnson JA, et al. Studies on neurotransmitter receptor systems in neocortex and hippocampus in senile dementia of the Alzheimer-type. J Neurol Sci 1984; 64: 109–17.
29. Reynolds GP, Arnold L, Rossor MN, Iversen LL, Mountjoy CQ, Roth M. Reduced binding of [3H]ketanserin to cortical 5-HT2 receptors in senile dementia of the Alzheimer type. Neurosci Lett 1984; 44: 47–51.
30. Bowen DM, Davison AN. Biochemical studies of nerve cells and energy metabolism in Alzheimer's disease. Br Med Bull (in press).
31. Pearson RCA, Esiri MM, Hiorns RW, Wilcock GK, Powell TPS. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer's disease. Proc Natl Acad Sci USA (in press).
32. Sims NR, Bowen DM, Neary D, Davison AN. Metabolic processes in Alzheimer's disease: adenine nucleotide content and production of 14CO2 from [U-14C]glucose in vitro in human neocortex. J Neurochem 1983; 41: 1329–34.
33. Sims NR, Finegan JM, Bowen DM, Blass JP. Mitochondrial function in Alzheimer's disease: measurement in vitro using neocortical tissue homogenates. J Neurochem 1985; 44(Suppl):S192A.
34. Davies P, Katz DA, Crystal HA. Choline acetyltransferase, somatostatin, and substance P in selected cases of Alzheimer's disease. In: Corkin S, Davies KL, Growdon JH, Usdin E, Wurtman RJ, eds. Alzheimer's disease: a report of progress. Vol. 9. New York: Raven Press, 1982:9–14.
35. Bowen DM, Benton JS, Spillane JA, Smith CCT, Allen SJ. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci 1982; 57: 191–202.
36. Bowen DM, Sims NR, Benton JS, et al. Treatment of Alzheimer's disease: a cautionary note. N Engl J Med 1981; 305: 1016.
37. Yates CM, Simpson J, Maloney AFJ, Gordon A. Neurochemical observations in a case of Pick's disease. J Neurol Sci 1980; 48: 257–63.
38. Growdon JH, Corkin S. Cerebrospinal fluid measures in Alzheimer's disease. In: Crook T, Ferris S, Bartus R, eds. Assessment in geriatric psychopharmacology. Mark Powley Associates, 1983:251–63.